177 related articles for article (PubMed ID: 25999251)
1. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model.
Spolverato G; Vitale A; Ejaz A; Kim Y; Cosgrove D; Schlacter T; Geschwind JF; Pawlik TM
Surgery; 2015 Aug; 158(2):339-48. PubMed ID: 25999251
[TBL] [Abstract][Full Text] [Related]
2. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis.
Mayo SC; de Jong MC; Bloomston M; Pulitano C; Clary BM; Reddy SK; Clark Gamblin T; Celinski SA; Kooby DA; Staley CA; Stokes JB; Chu CK; Arrese D; Ferrero A; Schulick RD; Choti MA; Geschwind JF; Strub J; Bauer TW; Adams RB; Aldrighetti L; Mentha G; Capussotti L; Pawlik TM
Ann Surg Oncol; 2011 Dec; 18(13):3657-65. PubMed ID: 21681380
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases.
Ercolani G; Cucchetti A; Cescon M; Peri E; Brandi G; Del Gaudio M; Ravaioli M; Zanello M; Pinna AD
Eur J Cancer; 2011 Oct; 47(15):2291-8. PubMed ID: 21652204
[TBL] [Abstract][Full Text] [Related]
4. Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis.
Spolverato G; Vitale A; Bagante F; Connolly R; Pawlik TM
Ann Surg; 2017 Apr; 265(4):792-799. PubMed ID: 28266967
[TBL] [Abstract][Full Text] [Related]
5. Liver Resection for Advanced Intrahepatic Cholangiocarcinoma: A Cost-Utility Analysis.
Cillo U; Spolverato G; Vitale A; Ejaz A; Lonardi S; Cosgrove D; Pawlik TM
World J Surg; 2015 Oct; 39(10):2500-9. PubMed ID: 26148521
[TBL] [Abstract][Full Text] [Related]
6. Hepatic Resection for Disappearing Liver Metastasis: a Cost-Utility Analysis.
Spolverato G; Vitale A; Ejaz A; Cosgrove D; Cowzer D; Cillo U; Pawlik TM
J Gastrointest Surg; 2015 Sep; 19(9):1668-75. PubMed ID: 26077902
[TBL] [Abstract][Full Text] [Related]
7. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.
Vitale A; Farinati F; Burra P; Trevisani F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Missale G; Foschi FG; Gasbarrini A; Svegliati Baroni G; Virdone R; Chiaramonte M; Spolverato G; Cillo U;
Liver Transpl; 2015 Oct; 21(10):1250-8. PubMed ID: 26183802
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis.
Gazelle GS; Hunink MG; Kuntz KM; McMahon PM; Halpern EF; Beinfeld M; Lester JS; Tanabe KK; Weinstein MC
Ann Surg; 2003 Apr; 237(4):544-55. PubMed ID: 12677152
[TBL] [Abstract][Full Text] [Related]
9. Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database.
Fairweather M; Swanson R; Wang J; Brais LK; Dutton T; Kulke MH; Clancy TE
Ann Surg Oncol; 2017 Aug; 24(8):2319-2325. PubMed ID: 28303430
[TBL] [Abstract][Full Text] [Related]
10. Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis.
Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
J Surg Oncol; 2018 Feb; 117(2):171-181. PubMed ID: 28940257
[TBL] [Abstract][Full Text] [Related]
11. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?
Xiang JX; Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
Ann Surg Oncol; 2018 Dec; 25(13):3928-3935. PubMed ID: 30218247
[TBL] [Abstract][Full Text] [Related]
12. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.
Gazelle GS; McMahon PM; Beinfeld MT; Halpern EF; Weinstein MC
Radiology; 2004 Dec; 233(3):729-39. PubMed ID: 15564408
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.
Cucchetti A; Piscaglia F; Cescon M; Colecchia A; Ercolani G; Bolondi L; Pinna AD
J Hepatol; 2013 Aug; 59(2):300-7. PubMed ID: 23603669
[TBL] [Abstract][Full Text] [Related]
14. Quality of life after treatment of neuroendocrine liver metastasis.
Spolverato G; Bagante F; Wagner D; Buettner S; Gupta R; Kim Y; Maqsood H; Pawlik TM
J Surg Res; 2015 Sep; 198(1):155-64. PubMed ID: 26095419
[TBL] [Abstract][Full Text] [Related]
15. Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?
Landman MP; Feurer ID; Pinson CW; Moore DE
HPB (Oxford); 2011 Nov; 13(11):783-91. PubMed ID: 21999591
[TBL] [Abstract][Full Text] [Related]
16. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.
Vitale A; Volk ML; Pastorelli D; Lonardi S; Farinati F; Burra P; Angeli P; Cillo U
Hepatology; 2010 Jan; 51(1):165-73. PubMed ID: 19877181
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery.
Spolverato G; Bagante F; Aldrighetti L; Poultsides G; Bauer TW; Field RC; Marques HP; Weiss M; Maithel SK; Pawlik TM
J Gastrointest Surg; 2017 Dec; 21(12):2039-2047. PubMed ID: 28744737
[TBL] [Abstract][Full Text] [Related]
18. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine liver metastasis: The chance to be cured after liver surgery.
Bagante F; Spolverato G; Merath K; Postlewait LM; Poultsides GA; Mullen MG; Bauer TW; Fields RC; Lamelas J; Marques HP; Aldrighetti L; Tran T; Maithel SK; Pawlik TM
J Surg Oncol; 2017 May; 115(6):687-695. PubMed ID: 28146608
[TBL] [Abstract][Full Text] [Related]
20. Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment.
Zhang XF; Beal EW; Chakedis J; Lv Y; Bagante F; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Weiss M; Pawlik TM
J Gastrointest Surg; 2017 Nov; 21(11):1821-1830. PubMed ID: 28730354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
